TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02208037
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MMF will be given at a dose of 15 mg/kg three times a day (TID) based upon ABW with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day 5 and discontinue after the last dose on Day 35, or may be continued if active GVHD is present.
Study: NCT01836198
Drug: Gemfibrozil
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01836198
Drug: Ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03833180
Drug: Zilovertamab vedotin
Normalized name: Zilovertamab vedotin
DrugBank: Zilovertamab vedotin (DB18457)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilovertamab vedotin administered via IV infusion per Schedule 1, 2, or 3 according to participant allocation.
Study: NCT02803060
Drug: Coppertone (BAY987516)
DrugBank: Copper (DB09130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formaulation number- SR15-62 -Z15-038).
Study: NCT02305381
Drug: semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.
Study: NCT04380298
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30ml of local infiltration solution containing 6mg ketorolac
Study: NCT00721032
Drug: Increased dose of amiodarone
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increase the dose of amiodarone according to the following scheme:~current dose -\> new dose 100 once daily (QD) -\> 200 QD; 200 QD -\> 400 QD; 300 QD -\> 600 QD; 400 QD -\> 600 QD
Study: NCT00006008
Drug: arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02176044
Drug: Sodium Nitroprusside infusion
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00369681
Drug: Bleomycin
Normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00369681
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00369681
Drug: Vinblastine
Normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02192723
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2\~6mg/day, twice per day, 8 weeks
Study: NCT02192723
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine, 400\~750mg/day, twice per day, 8 weeks
Study: NCT02192723
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine, 400～750mg/day, twice per day, 8 weeks
Study: NCT02192723
Drug: Ziprasidone
Normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ziprasidone 80\~160mg/day, twice per day, 8 weeks
Study: NCT02273700
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients are observed during their first month of Rivaroxaban (Xarelto®) treatment, which is part of their routine care.
Study: NCT02627898
Drug: green tea extract
Normalized name: Green Tea Extract
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract capsules, 400mg 1 time daily with the first bite of eat meal
Study: NCT02163655
Drug: FUROSEMIDE
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide, 20mg pills, will be administered every 24 houras, for a maximum of five days
Study: NCT02308098
Drug: Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02308098
Drug: Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02308098
Drug: Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02308098
Drug: Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01582503
Drug: MEMP1972A
Normalized name: MEMP1972A
DrugBank: Quilizumab (DB15176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous repeating dose
Study: NCT02246218
Drug: RAVICTI
Normalized name: Ravicti
DrugBank: Glycerol phenylbutyrate (DB08909)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04603833
Drug: SHR3680+Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive SHR3680 combined with Docetaxel
Study: NCT04603833
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive Docetaxel
Study: NCT00276666
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00276666
Drug: lomustine
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00276666
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03264547
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Every 3 weeks
Study: NCT03264547
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Every 3 weeks
Study: NCT03264547
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Every 3 weeks
Study: NCT03264547
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Every week
Study: NCT03264547
Drug: Eribulin
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered for 2 weeks and is then stopped to be administered for 1 week
Study: NCT00229710
Drug: Tesaglitazar
Normalized name: Tesaglitazar
DrugBank: Tesaglitazar (DB06536)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 in combination with insulin (with or without other oral antidiabetic drugs)
Study: NCT02205541
Drug: Eculizumab
Normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: According to the patient body weight, there will be 3 to 5 injections at D0, D7, D14, D21 and D28. According to the length of initial hospital stay, patients may have the remaining injections in the day ward of the recruiting center. Dosage of ECZ will be based on previous trials using ECZ in pediatric aHUS patients.~ECZ or placebo will be administrated intravenously as a 30-minute injection
Study: NCT04588818
Drug: Adalimumab plus Methotrexate
Normalized name: Methotrexate
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab 40 mg (≥30kg weight) or 20mg (\<30kg weight) subcutaneously every other week without loading dose.~Methotrexate(10 to 20 mg per square meter of body-surface area; maximum dose, 20 mg) .
Study: NCT00041756
Drug: PG-530742
Normalized name: PG-530742
DrugBank: PG-530742 (DB05495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 25 mg PG-530742 tablet, twice daily for for one year
Study: NCT00041756
Drug: 50 mg PG-530742
Normalized name: PG
DrugBank: PG-530742 (DB05495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 50 mg PG-530742 tablet, twice daily for for one year
Study: NCT00041756
Drug: 100 mg PG-530742
Normalized name: PG
DrugBank: PG-530742 (DB05495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg PG-530742 tablet, twice a day for one year
Study: NCT00041756
Drug: 200 mg PG-530742
Normalized name: PG
DrugBank: PG-530742 (DB05495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg PG-530742 tablet, twice a day for one year
Study: NCT03980184
Drug: Guanfacine
Normalized name: Guanfacine
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guanfacine 3mg/day Versus Placebo
Study: NCT00525135
Drug: Valproic Acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OUTLINE: This is a pilot study.~Patients receive valproic acid daily for 16 weeks. Dose increases on Days 4 and 8; dose remains the same for weeks 2-10. All patients will undergo a Thyrogen® (thyrotropin alfa for injection) RAI scan at entry to the study and after completion of 10 weeks of valproic acid treatment.~Quality of life is assessed at the end of every week through a study diary.~Patients are followed at 1, 2, 4, 6, 8, 10, 12, 14, 16, and 17 (Schedule 1) weeks. Patients return for follow-up at 3, 6, and 12 months.
Study: NCT00896025
Drug: N-acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be included in the trial from the onset of any hepatic coma grade and will receive NAC for the following 72 hrs.~NAC Solutions: The N-acetylcysteine will be added to 5% dextrose in defined concentrations according to the sequence of four specific doses required for the study.~i.Solution A: 150 mg/kg bodyweight in 250 ml 5% dextrose over one hour~ii.Solution B: 50 mg/kg in 500 ml 5% dextrose over four hours~iii.Solution C: 125 mg/kg in 1000 ml 5% dextrose over 19 hours~iv.Solution D: 150 mg/kg in 1000 ml 5% dextrose per 24 hours~v.Solution E: 150 mg/kg in 1000 ml 5% dextrose per 24 hours
Study: NCT04421742
Drug: Beclomethasone Dipropionate/Formoterol Fumarate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/FF NEXThaler® 100/6 μg b.i.d.
Study: NCT03498222
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered at a fixed dose of 1200 mg (equivalent to an average body weight-based dose of 15mg/kg) by intravenous (IV) infusion every 3 weeks (21 days).
Study: NCT03498222
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered at a fixed dose of 500mg/m2 by IV infusion every 3 weeks.
Study: NCT03498222
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered at a fixed dose of AUC5 by IV infusion every 3 weeks.
Study: NCT03498222
Drug: ADI PEG20
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered by intramuscular (IM) injection to patients once weekly.
Study: NCT01073800
Drug: atorvastatin 80 mg per os daily
Normalized name: atorvastatin 80 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atorvastatin 80 mg per os daily
Study: NCT03817112
Drug: Dexmedetomidine Hydrochloride 0.1 MG/ML
Normalized name: dexmedetomidine hydrochloride 0.1 MG/ML
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine Hydrochloride 0.1 MG/ML infusion at 0.2-0.7 mcg/kg/min
Study: NCT03817112
Drug: Propofol 10 MG/ML
Normalized name: propofol 10 MG/ML
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 10 MG/ML infusion at 0.3 -4 mg/kg/h
Study: NCT02529475
Drug: Gadoteric acid
Normalized name: Gadoteric acid
DrugBank: Gadoteric acid (DB09132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison with patients with Meniere's disease
Study: NCT01329939
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Age-dependent dose, nightly, 24 weeks
Study: NCT00260624
Drug: Escitalopram (Lexapro)
Normalized name: escitalopram Oral Tablet [Lexapro]
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00185224
Drug: SH D00264A (Triquilar)
Normalized name: Glutathione-SH
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 treatment cycles of 28 days each (no tablet-free intervals);Days 1-6: 0.03 mg EE + 0.05 mg LNG; Days 7-11: 0.04 mg EE + 0.075 mg LNG; Days 12-21: 0.03 mg EE + 0.125 mg LNG;Days 22-28: Placebo
Study: NCT01764828
Drug: Refametinib (BAY86-9766)
Normalized name: Refametinib
DrugBank: Refametinib (DB06309)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01764828
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00687674
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg orally Days 1, 8, 15, 22 of 28 day cycle
Study: NCT00687674
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase I - dose escalating: 200mg once daily dose level -2, 200mg once daily dose level -1, 200mg once daily dose level 0, 200mg twice daily dose level 1, 200mg twice daily dose level 2, 400mg AM \& 200mg PM daily dose level 2a, 400mg twice daily dose level 3 orally days 1-28 every 28 days until progression
Study: NCT00687674
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase I - dose escalating: 5mg level -2, 10mg level -1, 15mg level 0, 15mg level 1, 25mg level 2, 25mg level 2a, 25mg level 3 orally days 1-21 every 28 days until progression
Study: NCT02961881
Drug: blinatumomab
Normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Blinatumomab used as both continuous IV infusion and subcutaneous injection
Study: NCT05859802
Drug: Dalfampridine Pill
Normalized name: dalfampridine Pill
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were blinded and randomized into 2 groups; Group 1 received physical therapy 2 x a week for 12 weeks while taking dalfampridine 10 mg two times day
Study: NCT03716388
Drug: Mesalamine Granules
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalamine granules 4 grams a day
Study: NCT03971708
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic
Study: NCT03971708
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic
Study: NCT04235101
Drug: SYD985 + Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SYD985 powder for concentrate for solution for infusion Niraparib 100 mg per hard capsule
Study: NCT00217022
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 9 mg daily (three tablets)
Study: NCT03980132
Drug: Lugols Strong Iodine
Normalized name: Lugols Strong Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 L.I. drops / 8 hours for 10 days before surgery
Study: NCT00115947
Drug: Terlipressin
Normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04295018
Drug: C-CAR088
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10\^6 anti-BCMA CAR+T cells/kg. Other Name: CBM.BCMA Chimeric Antigen Receptor T cell.
Study: NCT00757978
Drug: memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: memantine 10mg twice a day
Study: NCT02969629
Drug: Apomorphine
Normalized name: Apomorphine
DrugBank: Apomorphine (DB00714)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00642798
Drug: sitagliptin phosphate
Normalized name: Sitagliptin Phosphate
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin 100mg once daily on Day 1 for single dose, and once daily on Day4-9 for multiple dose.
Study: NCT04369950
Drug: 3% 2-chloroprocaine and epidural morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidurals will be dosed with 3% 2-chloroprocaine to T4 level in 5ml increments, epidural morphine 3mg will be given after delivery of neonate. T4 level maintained throughout cesarean delivery with additional epidural doses of 2% lidocaine with 1:200,000 epinephrine for both groups. This is the critical component to bridge the latency period between the offset of 3% 2-chloroprocaine and the peak action of epidural morphine.Post-operative orders of scheduled acetaminophen and ibuprofen, and oxycodone as needed will be written.
Study: NCT00989963
Drug: Beraprost Sodium Modified Release
DrugBank: Beraprost (DB05229)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60µg Tablets, twice a day for 12 weeks
Study: NCT02576782
Drug: Perineural Dexamethasone and bupivacaine
Normalized name: bupivacaine and meloxicam
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02576782
Drug: intravenous saline plus perineural bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00068302
Drug: sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3-6 subjects will be enrolled into each dose level
Study: NCT03548467
Drug: Bempegaldesleukin
Normalized name: Bempegaldesleukin
DrugBank: Bempegaldesleukin (DB15140)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.006 mg/kg bempegaldesleukin (NKTR-214) will be administered intravenously q4w for up to 11 doses starting from week 11 or at any dosing visit up to week 34 and for up to week 50 (up to 11 doses). The first 2 doses will be in a Q3W interval and following doses in Q4W intervals.
Study: NCT01677858
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carfilzomib was administered as a 30-minute IV infusion on days 1, 8, and 15 of each 28-day treatment cycle.
Study: NCT01677858
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone was administered at a dose of 40 mg IV or orally (PO) on days 1, 8, 15, and 22 for the first 8 cycles; starting with cycle 9 dexamethasone was administered on days 1, 8, and 15.
Study: NCT02780544
Drug: Sucrose
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral sucrose before eye examination
Study: NCT00773747
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Four 100 mg capsules vorinostat taken orally, once daily, on Days 1 through 14 of each 21-day treatment cycle.
Study: NCT00773747
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.3 mg/m2 of bortezomib by IV push, on Days 1, 4, 8, and 11 of each 21-day treatment cycle.
Study: NCT01995019
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 ml single dose Intra-articular Depo-Medrol 40 mg/ml
Study: NCT01584492
Drug: beclomethasone+formoterol 50/6 (1 inhalation)
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
Study: NCT01584492
Drug: Formoterol + Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Formoterol HFA pMDI 6 µg / actuation~* Extrafine BDP HFA pMDI 50 µg/actuation
Study: NCT00150995
Drug: Tetrathiomolybdate
Normalized name: Tetrathiomolybdate
DrugBank: Tetrathiomolybdate (DB05088)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00773747
Drug: placebo to vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Four placebo capsules taken orally, once daily, on Days 1 through 14 of each 21-day treatment cycle.
Study: NCT00790920
Drug: Desmoteplase
Normalized name: Desmoteplase
DrugBank: Desmoteplase (DB04925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 μg/kg bodyweight, IV, single bolus over 1 - 2 minutes on 1st day
Study: NCT01065701
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal dexmedetomidine is given as premedication prior to induction of anesthesia
Study: NCT00258804
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03618316
Drug: Imeglimin
Normalized name: imeglimin
DrugBank: Imeglimin (DB12509)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 2 singles oral doses of imeglimin 1,500 mg (one at day 1 and one at day 8)
Study: NCT03618316
Drug: Cimetidine
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg of cimetidine bid from Day 5 to Day 10
Study: NCT01590693
Drug: Botulinum toxin A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: The children in Group 2 underwent bilateral treatment with a total of 12 units/kg bodyweight Botox® (Allergan, California, USA). Four injection sites in each calf - two in the proximal third of the lateral and medial gastrocnemius bellies and two distally in the gastrocnemius-soleus complex - were administered. All injections were performed with electromyogram amplifier guidance to ensure intramuscular position. Children in both groups were treated with four weeks of below knee walking casts. Children in group 2 received the casts 1-2 weeks after botulinum toxin A treatment.
Study: NCT01083589
Drug: Imatinib Mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral 400 mg daily
Study: NCT01083589
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2 over 1 hour intravenous infusion repeated every 21 days.
Study: NCT02540668
Drug: Lanabecestat
Normalized name: Lanabecestat
DrugBank: Lanabecestat (DB14814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally